ClinicalTrials.gg
Active, not recruitingNCT04261088Updated Oct 13, 2026

Assisted Suicide in Switzerland

An observational study in Assisted Suicide, sponsored by National Institutes of Health Clinical Center (CC). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by National Institutes of Health Clinical Center (CC) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Death with a site in United States — 13 open to participants now, 27 under way, 1 of them phase 3. Death · United States.

Enrollment
33rd of 39
25 · median 272
Started
2020
with 8 others
Observational
39 of 118
4 open now
Primary completion
2027-01
later than 11 of 26 live
Registered
74th of 118
by date

Among the 118 studies in Death with a site in United States, this one is the 33rd largest by enrollment of the 39 observational ones that give a count, is one of 9 that started in 2020, is one of 39 observational ones, reaches primary completion later than 11 of the 26 other live ones, and was the 74th registered.

Death

457 studies on the registry are indexed under Death; 85 are open to participants now.

Browse Death studies →

Open to participants now

13 of the 118 studies in Death with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 58 Death studies recruiting now, 43 (74%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Death with a site in United States, or all of them as a file.
02

Study summary

Background:

Researchers want to learn more about how the Swiss model of assisted suicide works. To do this, they have interviewed 25 Swiss experts. The researchers will draw on research in the fields of ethics, law, and medicine to analyze the transcripts.

Objective:

To describe the practice of assisted suicide in Switzerland and to study how the policy is carried out, how the right-to-die societies work, and the ethical implications of the practice.

Eligibility:

Swiss experts in the field of assisted suicide

Design:

The study includes 25 interviews that have already been conducted. The participants were:

  • academics
  • doctors and others in medical care
  • a government official
  • representatives of right-to-die societies.

Researchers will analyze the data using qualitative methods. Two researchers will develop a coding scheme and code the texts and analyze the data.

Read the detailed description

Switzerland is the only country in the world that enables assisted suicide by lay people, i.e.,

people who are not physicians. All other countries that have adopted aid-in-dying legislation

require that a physician provides this assistance. This project probes the reasons for adopting this policy, and the advantages and the disadvantages of the Swiss model at the end of life. Are the Swiss aid-in-dying volunteers able to provide well-informed assistance to patients in need? Is the Swiss model one to be followed by other nations? The project will focus on the work of the Swiss aid-in-dying societies. The study draws on research in the fields of ethics, law and medicine. Its novelty lies in incorporating different methods of analysis, reflecting on the right to die with dignity within a liberal framework that aims to respect fundamental human rights.

03

Conditions studied

  • Assisted Suicide

Browse trials for

Keywords

  • Ethics
  • Switzerland
  • End of life
  • Assisted Death
  • Natural History
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

25 transcripts of interviews with: Academics 14, Physicians and other medical care 6, Right to die associations 4, Government official 1

Eligibility criteria

  • INCLUSION/EXCLUSION:

The study includes 25 interviews with Swiss experts that have been conducted.

  • Gender: Men 14, Women 11
  • Backgrounds of interviewees: Academics 14, Physicians and other medical care 6, Right to die associations 4, Government official 1
  • Race and ethnicity: All white Swiss.
  • Age range: Unknown, but all are adults.
  • No vulnerable populations.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
25 participants (actual)

Groups and cohorts

  • Experts in Swiss assisted suicide

    Persons in Switzerland who are experts in how assisted suicide is practiced. We will beexamining already collected interviews.

06

What researchers measure

Primary outcomes

  1. Descriptive study

    This is a qualitative descriptive study of transcripts.

    Time frame: Ongoing

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Jan 2027, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2020
First posted
Feb 7, 2020
StartActual
Feb 3, 2020
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description
2 updates, last Oct 13, 2026
Show all 2 updates
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 8, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04261088
Responsible party
Sponsor
First posted
Feb 7, 2020
Start date
Feb 3, 2020
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Scott Y Kim, M.D.
principal investigator · National Institutes of Health Clinical Center (CC)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion